The story of Vioxx - No pain and a lot of gain: Ethical concerns regarding conduct of the pharmaceutical industry

Journal of Anesthesia

Volumn 20, Issue 4, 2006, Pages 348-351

  Cahana, Alex ^a   Mauron, Alexandre ^b  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

Ethics; Pain; Pharmaceutics; Vioxx

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB; STEROID;

ADENOMATOUS POLYP; ARTHRITIS; ARTICLE; CLINICAL PRACTICE; CLINICAL TRIAL; DRUG APPROVAL; DRUG COST; DRUG INDUSTRY; DRUG MARKETING; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; GASTROINTESTINAL HEMORRHAGE; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; INFLAMMATORY DISEASE; KIDNEY FAILURE; MEDICAL ETHICS; THROMBOEMBOLISM;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CLINICAL TRIALS; CYCLOOXYGENASE 2 INHIBITORS; DRUG APPROVAL; DRUG INDUSTRY; HUMANS; LACTONES; MARKETING; SULFONES;

EID: 33750491197     PISSN: 09138668     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00540-006-0432-7     Document Type: Article

References (9)

1. RH Miyoshi 2001 Systemic non-opioid analgesics JD Loeser Bonica's management of pain 3rd ed Lippincott Williams and Wilkins Philadelphia
2. FE Silverstein G Faich JL Goldstein LS Simon T Pincus A Whelton R Makuch G Eisen NM Agrawal WF Stenson AM Burr WW Zhao JD Kent JB Lefkowith KM Verburg GS Geis 2000 Gastrointestinal toxicity with celecoxib versus non-steroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: A randomized controlled trial JAMA 284 1247-1255 10979111 1:CAS:528:DC%2BD3cXmvFKmuro%3D 10.1001/ jama.284.10.1247
3. P Jüni AW Rutjes PA Dieppe 2002 COX-2 inhibitors superior to traditional non-steroidal anti-inflammatory drugs? BMJ 324 1287-1288 12039807 10.1136/bmj.324.7349.1287
4. C Bombardier L Laine A Reicin D Shapiro R Burgos-Vargas B Davis R Day MB Ferraz CJ Hawkey MC Hochberg TK Kvien TJ Schnitzer VIGOR Study Group 2000 Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR study group N Engl J Med 343 1520-1528 11087881 1:CAS:528:DC%2BD3cXos1OhurY%3D 10.1056/ NEJM200011233432103
5. E Woorlton 2002 What's all the fuss? Safety concerns about COX-2 inhibitors rofecoxib (Vioxx) and celecoxib (Celebrex) CMAJ 166 1692-1693
6. EJ Topol 2004 Failing the public health - rofecoxib, Merck and the FDA N Engl J Med 351 1707-1709 15470193 1:CAS:528:DC%2BD2cXovFSks7g%3D 10.1056/ NEJMp048286
7. P Jüni L Nartey S Reichenbach R Sterchi PA Dieppe M Egger 2004 Risk of cardiovascular events and rofecoxib: Cumulative meta-analysis Lancet 364 2021-2029 15582059 10.1016/S0140-6736(04)17514-4
8. EJ Topol GW Falk 2004 A coxib a day won't keep the doctor away Lancet 364 639-640 15325809 10.1016/S0140-6736(04)16906-7
9. MJ James LG Cleland 2004 Applying a research ethics committee approach to a medical practice controversy: The case of the selective COX-2 inhibitor rofecoxib J Med Ethics 30 182-184 15082814 1:STN:280:DC%2BD2c7os1Clsw%3D%3D 10.1136/jme.2003.004515